Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer | Synapse
September 13, 2024
Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
ctDNA tumor fraction to prognosticate overall survival on enzalutamide post-abiraterone by treatment arm